• 2020 GAPNA Pharmacology Conference: Contemporary Pharmacology and Prescribing in Older AdultsJoin us at the 2020 GAPNA Pharmacology Conference:
    Contemporary Pharmacology and Prescribing in Older Adults

    April 14-18, 2020, Honolulu, HI.

    Earn up to 18 CNE hours.

     

    Find out more about it and REGISTER today!

  • 2019 Senior Report Senior Report: Older Americans have more options for home care, but still struggling.

    The United Health Foundation has released results of a sweeping new study benchmarking the health of older adults. The America's Health Rankings® Senior Report was created in partnership with GAPNA to improve the health of America's seniors.

    The data will help advanced practice nurses and other providers deliver quality care.

    Find out about it!

  • AwardNew for GAPNA members: MCM Education

    GAPNA has partnered with a MCM Education to offer an ongoing series of CNE programs available to GAPNA members. "Diagnosing and Managing Parkinson’s Disease in Older Adults," is the latest program offered.

    Parkinson’s disease (PD) is characterized by both motor and nonmotor symptoms. It is diagnosed based on the presence of two of four motor symptoms including rest tremor, bradykinesia, rigidity, and gait imbalance...

    Find out about it!

  • FREE continuing education credit is available for the following session:

    "Meaningful Conversations throughout the Course of Illness"

    (session captured at the GAPNA 2018 Annual Conference)


    For November/December 2019 - Get Your Free CNE Now!

Amyloid Brain Changes

Genetic Risk Variants Linked to Alzheimer’s Amyloid Brain Changes at Different Stages of Disease

New National Institute on Aging (NIA)-supported research ties several genetic risk variants for late-onset Alzheimer’s disease to levels of amyloid at different disease stages.

The results, published online January 16, 2018, in JAMA Neurology, provide insight into the genetic influences on Alzheimer’s-related brain changes, namely, buildup of amyloid, a protein that turns toxic and accumulates in the brains of people with Alzheimer’s disease.

There is growing evidence of a strong genetic component to Alzheimer’s disease. In this study, researchers sought to better understand the genetic contributions to late-onset Alzheimer’s, beyond those related to APOE4, the strongest known genetic risk factor for the disease.

Researchers from the Indiana University School of Medicine, Indianapolis, and the David Geffen School of Medicine at the University of California, Los Angeles, analyzed associations between the top 20 Alzheimer’s genetic risk variants, as well as other variants previously associated with amyloid deposition, and amyloid levels measured by brain imaging.

The study included 977 participants (average age 74 years) from the NIA-supported Alzheimer’s Disease Neuroimaging Initiative: 322 who were cognitively normal, 496 who were in the mild cognitive impairment stage, and 159 who were in the dementia stage.

Findings showed that after APOE4, the gene with the strongest association with amyloid deposits was ABCA7, especially in the asymptomatic and early symptomatic disease stages. Studies have previously connected ABCA7 with Alzheimer’s disease processes in the brain; these findings provide further evidence of its role.

Research has also shown that African Americans are more likely than Whites to have a variant of the ABCA7 gene, with almost double the risk of developing Alzheimer’s.

Other Alzheimer’s disease risk genes found to be associated with amyloid buildup at different disease stages included FERMT2, which was most pronounced in people with mild cognitive impairment; SORL1 and EPHA1, which were associated with both the mild cognitive impairment and dementia stages; and CLU, DSG2, and ZCWPWI, which were linked to the dementia stage.

Results suggest genetic variants might affect Alzheimer’s disease processes differently across disease stages.

Researchers noted that improved understanding of these genetic risk factors could help predict which people are most at risk of developing dementia due to Alzheimer’s and identify gene-specific drug targets.

For more info, see Apostolova L.G. et al. (2018). Associations of the top 20 Alzheimer disease risk variants with brain amyloidosis. JAMA Neurology. doi:10.1001/jamaneurol.2017.4198. [Epub ahead of print]

Plan your trip to the nation’s capital during the GAPNA Annual Conference, September 26-29, 2018 by checking out all the things to do, places to eat, and ways to have fun.

Find out about it!